Delivery Order SPE2DB20D3303-SPE2DB25FZ4L7

Award Date 3/31/25
Potential Completion Date 4/1/25
Potential Value $9.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,347.24 firm fixed-price delivery order is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of February 14, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,481.49 firm-fixed-price delivery order is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of February 3, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,409.68, is for the supply of Candesartan Cilexetil 32 mg tablets. The contract has an ultimate completion date of March 6, 2025 and does not have a set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,894.21 firm fixed-price delivery order is for the supply of candesartan cilexetil 16 mg tablets to support military healthcare programs. The contract has an ultimate completion date of November 7, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,854.92, is a delivery order for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of March 21, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,236.17, is a delivery order for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of December 17, 2024 and is a firm fixed price contract. AmerisourceBergen Drug Corp is the prime contractor, and there are no set-aside requirements indicated for this award. This...
This federal contract award, valued at $7,632.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of Candesartan Cilexetil 16 mg tablets, a cardiovascular medication. The contract has an ultimate completion date of October 23, 2024 and was awarded on October 22, 2024. It is a firm fixed-price contract, with no set-aside designation....
This is a federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,498.49, is for the delivery of 32 mg Candesartan Cilexetil tablets in 90-count bottles. The contract is a firm fixed-price delivery order with a completion date of March 13, 2025. This award is not associated with a set-aside program. AmerisourceBergen Drug Corp holds a significant $999,999,999...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $11,854.68 for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of July 22, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Candesartan Cilexetil 8 mg tablets. The contract, valued at $1,113.48, has a period of performance through February 4, 2025 and is a Firm Fixed Price contract type. The contract is not designated under any set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
  • SPE2DB20D3303
    Indefinite Delivery Contract
  • SPE2DB20D3303-SPE2DB25FZ4L7
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,368.68, is for the supply of Candesartan Cilexetil 16 mg tablets. The contract has an ultimate completion date of April 1, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award was not designated as a set-aside.

Generated 6/30/25, 10:49 AM